RxDoctor Payments Data

Yu Sun, MD

Internal Medicine · Middletown, NYNPI 1558702480

Payments from drug & device makers

$1,640in general payments, 2019–2025

Across 79 payments — averaging $20.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$125
  • Madrigal Pharmaceuticals$121
  • AbbVie$70
  • Amgen$47
  • Redhill Biopharma Inc.$20
  • plus $45 from 3 others

What the payments were for

  • Food & beverage$1,640100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,640 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$65,528
Medicare patients
73
Services billed
1,135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VemlidyTenofovir Alafenamide159$237,222
VascepaIcosapent Ethyl565$207,579
JanuviaSitagliptin Phosphate260$175,970
Diclofenac Epolamine369$164,404
ProliaDenosumab57$95,795
FarxigaDapagliflozin Propanediol111$83,887
CreonLipase/Protease/Amylase57$79,186
EliquisApixaban74$48,836
OzempicSemaglutide44$40,175
RybelsusSemaglutide30$29,803
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate21$27,216
RestasisCyclosporine40$25,439
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$19,028
BaracludeEntecavir12$16,561
ZenpepLipase/Protease/Amylase22$16,438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$1,212$237,222159 claims
AbbVieCreon, Restasis, Linzess$70$112,991113 claims
AmgenProlia$47$95,79557 claims
Novo NordiskOzempic, Rybelsus$19$69,97874 claims
PfizerEliquis$13$48,83674 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Middletown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →